Health for All – Our Collaborations Supporting the SDGs
A knowledge hub highlighting over 250 collaborations between the innovative biopharmaceutical industry and more than 1200 partners to support the SDGs.
Read more
Geneva, May 19, 2020: At the Seventy-Third World Health Assembly, IFPMA, the industry body representing the innovative biopharmaceutical industry delivered a joint statement on behalf of the global interests of broad innovative health industries, reasserting that they stand united with governments and global health stakeholders worldwide to combat COVID-19. The biopharmaceutical industry is joined by...
Read moreThis was originally published in the Financial Times on Sunday, May 17, 2020. We must not send the wrong message to pharma companies that have taken huge risks As we confront an unprecedented public health, social and economic crisis brought about by Covid-19, our hopes are pinned on scientific innovation and, in particular, potential treatments...
Read moreOur organizations believe that coordinated, inclusive, and multi-stakeholder action is the only possible solution to mitigate the impact of this unprecedented global health emergency, and believe the private sector must be an equal partner in coordination efforts. As WHO’s Director General has recently stated, “the private sector has an essential role to play in combating...
Read moreDuring these unprecedented times, it is essential that we all come together to contribute to the development of medicines and vaccines for treatment and prevention of COVID-19. Many activities, undertaken by governments, national regulatory authorities (NRAs), academia, global health stakeholders and the biopharmaceutical industry, are helping to identify, research, develop and manufacture at scale these...
Read moreThomas Cueni, IFPMA Director-General, spoke to CNN about the challenges to be faced in the manufacturing of a COVID-19 vaccine on a large-scale and how the industry, as a whole, will respond to the challenges. 00:02 to 1:04 (Transcript of Thomas Cueni’s part) ANNA STEWART, CNN REPORTER (AS): At least, 100 COVID-19 vaccines are in development...
Read moreLast week, high-level representatives from seven companies – Takeda, Merck, AstraZeneca, CSL Behring, MSD, Pfizer and Sandoz – took part in a second IFPMA COVID-19 virtual media briefing dedicated to the on-going R&D efforts to find a treatment for COVID-19. It was an important milestone, taking stock of all that has been achieved in little...
Read moreA knowledge hub highlighting over 250 collaborations between the innovative biopharmaceutical industry and more than 1200 partners to support the SDGs.
Read more
On Monday, 4 May 2020, David Ricks, IFPMA President and Chairman and CEO of Eli Lilly, delivered a video statement at the Global Response Pledging Conference convened by the European Commission together with the WHO (YouTube). The objective of the conference was to raise 7.5bn EUR to ramp up work on vaccines, diagnostics and treatments...
Read moreGeneva, 4 May, 2020: The world’s leading biopharmaceutical companies today reaffirmed the industry’s commitment to join forces to ensure that its breadth of expertise in therapeutics (research, clinical development, manufacturing) is shared across the scientific community as part of the global fight against COVID-19. Today, the industry recommitted at the Coronavirus Global Response Pledging Marathon,...
Read moreIndianapolis/Brussels, 4 May 2020 Statement delivered by: David Ricks, President of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and CEO of Eli Lilly (2 minutes) Greeting: My name is Dave Ricks. As the Chairman of IFPMA, the International Federation of Pharmaceutical Manufacturers and Associations, and as CEO of Lilly, I am pleased to...
Read more